object
focu
potenti
benefici
effect
pleiotrop
effect
dipeptidyl
inhibitor
attenu
progress
diabet
kidney
diseas
reduc
longterm
effect
acut
kidney
injuri
aki
chronic
kidney
diseas
ckd
transit
analyz
patient
diabet
wean
dialysisrequir
aki
identifi
cox
proport
hazard
model
inverseweight
estim
probabl
treatment
use
adjust
treatment
select
bia
outcom
incid
endstag
renal
diseas
esrd
mortal
major
advers
cardiovascular
event
hospit
heart
failur
result
total
patient
diabet
wean
dialysisrequir
aki
identifi
patient
nonus
patient
user
compar
nonus
user
lower
risk
esrd
hazard
ratio
ci
allcaus
mortal
hazard
ratio
ci
p
adjust
ckd
advanc
ckd
angiotensinconvert
enzym
inhibitor
angiotensin
ii
receptor
blocker
use
contrast
risk
major
advers
cardiovascular
event
hospit
heart
failur
differ
significantli
group
conclus
dipeptidyl
inhibitor
user
lower
risk
esrd
mortal
nonus
among
patient
diabet
wean
dialysisrequir
aki
therefor
prospect
studi
aki
ckd
transit
episod
aki
need
optim
target
intervent
iabet
mellitu
dm
known
worsen
outcom
cardiovascular
renal
diseas
dm
milieu
potenti
increas
risk
acut
kidney
injuri
aki
addit
longterm
mortal
morbid
increas
ischemia
sensit
kidney
acut
kidney
injuri
known
increas
risk
chronic
kidney
diseas
ckd
endstag
renal
diseas
esrd
especi
diabet
becom
increas
burden
health
care
resourc
recent
american
societi
nephrolog
acut
kidney
injuri
advisori
group
highlight
transit
care
potenti
opportun
reduc
longterm
effect
aki
howev
pauciti
data
intervent
reduc
morbid
mortal
aki
acut
kidney
diseas
survivor
dipeptidyl
inhibit
new
treatment
approach
dm
dipeptidyl
inhibitor
protect
kidney
via
antiinflammatori
activ
earli
stage
diabet
nephropathi
beyond
lower
glucos
level
inhibit
amelior
kidney
fibrosi
antioxid
properti
proteinprotein
interact
nonetheless
inform
limit
clinic
outcom
patient
diabet
develop
aki
receiv
howev
outcom
episod
aki
simpli
regard
binari
administr
long
term
renal
replac
therapi
recoveri
thu
studi
aim
examin
effect
outcom
wean
dialysisrequir
aki
akid
sever
form
aki
focus
risk
esrd
mortal
cardiovascular
outcom
nation
health
insur
nhi
program
offer
comprehens
medic
care
coverag
countri
popul
million
inhabit
taiwan
nation
health
research
institut
releas
nation
health
insur
research
databas
nhird
research
purpos
data
encrypt
protect
privaci
databas
contain
inform
outpati
consult
hospit
procedur
prescript
record
within
nhi
system
nhi
data
reliabl
nhi
administr
routin
audit
claim
data
prevent
fraud
nhi
program
diseas
diagnos
regist
nhird
classifi
accord
intern
classif
diseas
ninth
revis
clinic
modif
baselin
comorbid
compil
least
outpati
visit
inpati
claim
within
year
index
hospit
first
dialysi
rule
construct
basi
rel
strict
criterion
well
valid
good
predict
power
person
inform
deidentifi
nhird
inform
consent
waiv
studi
exempt
full
ethic
review
institut
review
board
nation
taiwan
univers
hospit
institut
review
board
number
identifi
adult
patient
dm
accord
code
hospit
discharg
dialysisrequir
aki
identifi
use
intern
classif
diseas
ninth
revis
code
aki
figur
depict
algorithm
use
patient
select
studi
particip
select
citizen
akid
cover
taiwan
nhi
januari
juli
definit
dm
cohort
base
follow
criteria
visit
least
outpati
clinic
least
admiss
diagnosi
dm
code
diagnost
accuraci
dm
previous
valid
good
predict
power
use
cutoff
period
immedi
index
hospit
identifi
preadmiss
aki
dialysi
patient
preadmiss
aki
esrd
undergon
kidney
transplant
exclud
dipeptidyl
inhibitor
avail
taiwan
sinc
march
thu
includ
patient
diagnos
type
dm
march
june
inclus
patient
follow
decemb
allow
least
halfyear
followup
estim
risk
outcom
event
dipeptidyl
inhibitor
user
identifi
enrol
hospit
discharg
first
wean
akid
index
date
date
first
prescript
particip
control
cohort
patient
without
use
assign
index
date
correspond
patient
cohort
investig
patient
medic
adher
effect
mortal
calcul
patient
medic
possess
ratio
mpr
select
patient
group
mpr
less
target
group
contrast
nonus
patient
use
year
enrol
mean
mpr
address
confound
observ
covari
use
invers
probabl
treatment
weight
iptw
method
form
propens
scoreematch
analysi
weight
base
result
treatment
select
model
estim
use
logist
regress
receipt
therapi
depend
variabl
baselin
characterist
independ
variabl
variabl
use
propens
scoreematch
analysi
includ
analysi
p
valu
less
patient
weight
invers
probabl
receiv
treatment
actual
receiv
weight
calcul
basi
propens
scoreematch
valu
weight
user
invers
propens
score
weight
nonus
invers
e
propens
score
process
iptw
gener
new
pseudocohort
process
enabl
us
preserv
sampl
size
pseudocohort
close
origin
cohort
albeit
strictli
equival
weight
assess
balanc
baselin
characterist
among
treatment
group
use
chisquar
test
categor
variabl
student
test
continu
variabl
primari
outcom
studi
allcaus
mortal
esrd
hospit
discharg
secondari
outcom
major
advers
cardiovascular
event
mace
defin
incid
coronari
event
includ
nonfat
myocardi
infarct
mi
coronari
arteri
bypass
graft
coronari
angiographi
intern
classif
diseas
ninth
revis
code
mi
hospit
high
accuraci
valid
previou
studi
record
regard
coronari
arteri
bypass
graft
angiographi
reliabl
construct
basi
nhi
procedur
code
coupl
nhi
reimburs
system
routin
audit
defin
patient
advanc
ckd
creatinin
level
mgdl
convert
mmoll
multipli
prescript
concomit
erythropoiesisstimul
agent
accord
reimburs
regul
nhi
followup
start
first
day
use
end
decemb
time
incid
outcom
interest
date
death
last
reimburs
record
characterist
nonus
user
compar
use
student
test
age
chisquar
test
variabl
incid
rate
outcom
interest
compar
user
nonus
use
poisson
distribut
treatment
effect
hazard
ratio
hr
ci
continu
next
page
main
outcom
interest
model
use
cox
proport
hazard
regress
incorpor
iptw
estim
use
propens
scoreematch
analysi
importantli
weight
cox
model
addit
control
ckd
advanc
ckd
medic
therapi
estim
year
discharg
angiotensinconvert
enzym
inhibitor
angiotensin
ii
receptor
blocker
use
examin
medic
prescrib
treatment
assign
sensit
analys
perform
estim
overal
hr
user
vs
nonus
assess
potenti
heterogen
treatment
effect
allcaus
mortal
esrd
mace
hospit
heart
failur
hhf
analyz
use
postiptw
cohort
formal
test
firstord
interact
use
multivari
cox
proport
hazard
model
enter
interact
term
use
subgroup
variabl
interact
use
clinic
relev
variabl
includ
oral
antidiabet
agent
ie
metformin
sulfonylurea
thiazolidinedion
insulin
meglitinid
aglucosidas
inhibitor
test
analys
perform
use
sa
version
sa
institut
inc
p
valu
less
consid
statist
signific
total
particip
diagnosi
aki
receiv
hemodialysi
januari
juli
identifi
recruit
figur
overal
total
patient
type
dm
withdrew
dialysi
includ
analysi
patient
nonus
patient
user
demograph
clinic
characterist
cohort
iptw
estim
summar
tabl
dipeptidyl
inhibitor
user
younger
lower
proport
chronic
obstruct
pulmonari
diseas
chronic
liver
diseas
furthermor
user
group
like
receiv
clopidogrel
statin
antidiabet
agent
includ
thiazolidinedion
meglitinid
aglucosidas
inhibitor
tabl
result
cox
model
adjust
presenc
ckd
advanc
ckd
angiotensinconvert
enzym
inhibitor
angiotensin
ii
receptor
blocker
use
evalu
effect
interact
use
concomit
use
antidiabet
agent
outcom
effect
risk
esrd
consist
among
patient
subgroup
stratifi
combin
antidiabet
agent
howev
combin
insulin
increas
risk
mortal
hhf
p
addit
combin
meglitinid
increas
risk
mortal
aglucosidas
inhibitor
increas
risk
hhf
tabl
result
subgroup
analys
differ
outcom
present
figur
dipeptidyl
inhibitor
use
consist
associ
lower
probabl
longterm
esrd
figur
mortal
risk
figur
b
across
variou
patient
group
respect
baselin
comorbid
hhf
patient
previou
cerebrovascular
diseas
insulin
use
higher
risk
hhf
figur
c
research
first
attempt
examin
effect
use
renal
outcom
patient
diabet
wean
akid
result
highlight
decreas
risk
mortal
esrd
respect
mean
followup
year
studi
cohort
moreov
risk
mace
hhf
significantli
increas
user
dipeptidyl
inhibitor
use
decreas
subsequ
esrd
acut
kidney
injuri
episod
associ
cumul
risk
develop
advanc
ckd
patient
dm
mani
studi
report
associ
increas
risk
esrd
subsequ
aki
despit
surviv
withdraw
dialysi
aki
increas
incid
de
novo
ckd
longterm
dialysi
death
hypoxia
serv
key
player
aki
pathophysiolog
final
common
pathway
ckd
esrd
acut
kidney
injuri
contribut
tubular
atrophi
interstiti
fibrosi
peritubular
capillari
effac
thu
maladapt
repair
aki
lead
acceler
kidney
age
ckd
patholog
process
initi
aki
eg
hypoxia
cellular
senesc
maladapt
repair
inflamm
propos
character
aki
ckd
transit
primarili
via
selfperpetu
tubulointerstiti
fibrosi
pathway
renal
repair
maladapt
tissu
respons
includ
inflamm
fibrosi
activ
interstiti
myofibroblast
vascular
rarefact
often
lead
persist
cell
tissu
malfunct
eventu
chronic
fibrot
kidney
diseas
sever
studi
illustr
pleiotrop
effect
delay
renal
function
deterior
dipeptidyl
inhibitor
may
prevent
inflamm
fibrosi
heart
kidney
decreas
oxid
stress
respons
heart
kidney
tissu
experiment
studi
use
variou
diabet
model
suggest
incretin
protect
vascular
endothelium
injuri
bind
glucagonlik
peptid
receptor
therebi
amelior
oxid
stress
local
inflammatori
respons
reduc
albuminuria
inhibit
glomerular
sclerosi
renal
effect
might
explain
indirectli
glucoseindepend
mechan
improv
blood
pressur
control
via
downregul
sodiumhydrogen
antiport
proxim
tubul
vildagliptin
report
decreas
apoptosi
evidenc
decreas
b
cell
x
proteinb
cell
messeng
rna
express
significantli
decreas
messeng
rna
express
proinflammatori
marker
cxc
motif
chemokin
ischemiareperfus
injuri
anim
model
macrophag
phenotyp
switch
subtyp
facilit
renal
repair
aki
anim
studi
sitagliptinmedi
inhibit
earli
atherosclerosi
due
polar
monocyt
differenti
via
stromal
cellderiv
factor
chemokin
receptor
type
signal
facilit
kidney
repair
renal
recoveri
aki
compromis
perturb
cell
cycl
arrest
phase
product
proinflammatori
profibrot
signal
suggest
may
improv
oxygen
suppli
mitig
inflammatori
respons
ischemiareperfus
injuri
improv
recoveri
subleth
injur
cell
furthermor
immun
system
act
marker
tcell
activ
function
costimulatori
molecul
kidney
injuri
adjust
age
sex
chronic
kidney
diseas
advanc
chronic
kidney
diseas
angiotensinconvert
enzym
inhibitor
angiotensin
ii
receptor
blocker
use
c
hospit
primari
diagnosi
heart
failur
express
activ
cell
well
injur
renal
tubular
epitheli
cell
thu
chronic
express
may
provid
mechanist
link
aki
subsequ
renal
fibrosi
possibl
inactiv
cell
identifi
primari
pathogen
cell
experiment
aki
may
attenu
express
although
sever
smallscal
clinic
trial
found
significantli
decreas
urin
albumintocreatinin
ratio
largescal
random
doubleblind
studi
reveal
ad
routin
care
appear
increas
risk
renal
failur
clinic
trial
date
provid
clear
consensu
renal
effect
drug
patient
type
dm
enhanc
followup
renal
function
patient
recov
temporari
dialysi
may
warrant
may
candid
agent
prevent
renal
diseas
progress
patient
dm
wean
akid
adjust
hr
longterm
risk
incid
endstag
renal
diseas
b
allcaus
mortal
c
hospit
heart
failur
among
user
nonus
subgroup
analysi
respect
premorbid
risk
concomit
medic
adjust
age
sex
chronic
kidney
diseas
advanc
chronic
kidney
diseas
acei
arb
use
acei
angiotensinconvert
enzym
inhibitor
arb
angiotensin
ii
receptor
blocker
dipeptidyl
inhibitor
hr
hazard
ratio
nt
new
taiwan
dollar
aki
acut
kidney
injuri
requir
temporari
dialysi
increas
longterm
risk
coronari
event
allcaus
mortal
reduct
mi
cardiovascular
event
observ
shortterm
treatment
persist
long
term
dipeptidyl
inhibitor
may
cardiovascular
benefit
lowrisk
patient
enrol
neutral
effect
high
risk
previou
cardiovascular
event
particip
cardiovascular
outcom
trial
dipeptidyl
inhibitor
found
prevent
develop
aortic
endotheli
stiff
via
decreas
fibroblast
growth
factor
oxid
stress
increas
klotho
express
mice
high
level
serum
fibroblast
growth
factor
klotho
defici
associ
increas
risk
coronari
heart
diseas
heart
failur
cardiovascular
mortal
dipeptidyl
inhibitor
improv
cardiac
function
decreas
infarct
size
mi
stromal
cellderiv
factor
chemokin
receptor
type
transduc
activ
transcript
signal
pathway
cardiomyocyt
accordingli
preliminari
report
establish
vildagliptin
sitagliptin
treatment
reduc
intima
media
thick
surrog
marker
earli
atherosclerosi
studi
found
use
patient
diabet
wean
akid
result
lower
risk
allcaus
mortal
recent
metaanalysi
report
decreas
risk
allcaus
mortal
patient
ckd
furthermor
mogensen
et
al
illustr
lower
mortal
rate
danish
popul
diabet
take
incretinbas
drug
recent
observ
data
also
confirm
may
improv
cardiac
allcaus
mortal
patient
dm
hhf
even
patient
preexist
heart
failur
found
may
decreas
risk
macerel
mortal
sever
sepsi
supplement
tabl
avail
onlin
http
wwwmayoclinicproceedingsorg
use
could
explain
decreas
risk
mortal
studi
one
studi
found
use
sitagliptin
patient
type
diabet
recent
acut
mi
associ
increas
risk
advers
cardiovascular
event
anoth
studi
note
improv
longterm
surviv
patient
diabet
first
acut
mi
diabet
infecti
caus
death
link
inflamm
becom
increasingli
appreci
ckd
character
state
chronic
inflamm
wealth
evid
indic
disord
innat
adapt
immun
system
contribut
increas
rate
infect
cours
ckd
diabet
dipeptidyl
inhibit
may
pleiotrop
effect
modul
immun
hepat
c
viru
sitagliptin
reduc
lipopolysaccharideinduc
inflammatori
respons
mediat
nuclear
factor
kb
signal
pathway
although
anim
studi
may
hint
may
function
cardiac
remodel
attribut
sepsisinduc
inflamm
although
concomit
effect
incid
esrd
describ
studi
found
combin
insulin
meglitinid
therapi
increas
risk
mortal
patient
diabet
aki
concept
line
observ
meglitinid
antidiabet
agenteinduc
hypoglycemia
eventu
contribut
cardiovascular
event
allcaus
mortal
recent
studi
also
report
meglitinid
combin
insulin
increas
hypoglycemia
patient
advanc
ckd
accordingli
augment
longterm
effect
insulin
subsequ
heart
failur
posteakid
care
studi
sever
strength
first
studi
first
report
associ
use
lower
risk
esrd
allcaus
mortal
patient
diabet
wean
akid
studi
popul
includ
patient
dm
hospit
aki
result
consist
patient
comorbid
congest
heart
failur
cardiovascular
diseas
receiv
angiotensinconvert
enzym
inhibitor
angiotensin
ii
receptor
blocker
second
data
deriv
current
nationwid
populationbas
cohort
enabl
trace
nearli
aki
episod
associ
use
claim
record
outpati
visit
hospit
admiss
includ
diagnos
includ
sourc
studi
limit
acknowledg
first
given
imposs
treatment
random
retrospect
observ
studi
influenc
potenti
confound
factor
evalu
herein
may
bias
result
exampl
laboratori
data
eg
hemoglobin
level
avail
nhird
claim
data
howev
use
surrog
indic
adjust
patient
baselin
diabet
sever
number
outpati
visit
ad
frequenc
hemoglobin
measur
final
model
found
similar
result
supplement
result
avail
onlin
http
wwwmayoclinicproceedingsorg
high
blood
pressur
wellknown
key
progress
kidney
diseas
death
blood
pressur
data
nhird
use
joint
model
multipl
diseas
captur
effect
hypertens
investig
geograph
variat
risk
recent
studi
report
congest
heart
failur
atrial
fibril
peripher
arteri
diseas
highli
relat
hypertens
could
use
proxi
hypertens
although
variabl
directli
reflect
hypertens
could
assum
control
effect
hypertens
includ
abovement
diseas
proxi
hypertens
ad
final
model
supplement
result
avail
onlin
http
wwwmayoclinicproceedingsorg
avoid
potenti
residu
confound
due
inadequ
adjust
unevalu
bias
use
iptw
model
balanc
everi
clinic
characterist
group
addit
match
patient
use
propens
score
analysi
propens
score
reanalyz
mortal
use
propens
scoreeadjust
logist
regress
consist
iptw
analysi
propens
scoreematch
analysi
reveal
use
mitig
mortal
patient
diabet
wean
akid
supplement
tabl
avail
onlin
http
wwwmayoclinicproceedingsorg
second
implicit
associ
insulin
use
intens
glycem
control
may
potenti
confound
result
although
result
stratifi
analysi
accord
insulin
use
consist
main
analysi
although
estim
glomerular
filtrat
rate
ckd
stage
classif
nhird
devis
way
differenti
sever
ckd
use
nhi
data
categor
patient
ckd
concomit
erythropoiesisstimul
agent
prescript
advanc
ckd
patient
advanc
ckd
found
anem
therefor
patient
prescript
highli
like
advanc
ckd
adjust
preadmiss
ckd
advanc
ckd
postdischarg
ckd
advanc
ckd
found
patient
advanc
ckd
use
discharg
independ
associ
decreas
mortal
importantli
factor
exhibit
severitydepend
risk
mortal
final
futur
studi
clarifi
mechan
underli
differ
incid
esrd
differ
howev
result
may
generaliz
popul
dm
aki
episod
cover
univers
health
care
insur
program
find
suggest
use
patient
diabet
wean
akid
associ
decreas
risk
esrd
mortal
find
extend
previou
studi
safeti
use
may
shed
light
manag
aki
ckd
transit
care
potenti
renal
effect
may
aid
treatment
decis
routin
clinic
practic
sincer
thank
staff
taiwan
clinic
trial
consortium
tctc
nation
taiwan
univers
hospit
studi
group
acut
renal
failur
nsarf
includ
follow
vincent
wu
md
phd
depart
intern
medicin
nation
taiwan
univers
hospit
taipei
tai
supplement
materi
found
onlin
http
wwwmayoclinicproceedingsorg
supplement
materi
attach
journal
articl
edit
author
take
respons
accuraci
data
